NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Antonio Jimeno
University of Colorado Denver - Denver / United States
Others
AD Scientific Index ID: 1775599
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Antonio Jimeno's MOST POPULAR ARTICLES
1-)
The immune landscape of cancerV Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...Immunity 48 (4), 812-830. e14, 201847272018
2-)
Core signaling pathways in human pancreatic cancers revealed by global genomic analysesS Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ...science 321 (5897), 1801-1806, 200847092008
3-)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetC Gravalos, A JimenoAnnals of oncology 19 (9), 1523-1529, 200813012008
4-)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ...The Lancet 393 (10167), 156-167, 201914662019
5-)
Patient-derived tumour xenografts as models for oncology drug developmentJJ Tentler, AC Tan, CD Weekes, A Jimeno, S Leong, TM Pitts, JJ Arcaroli, ...Nature reviews Clinical oncology 9 (6), 338-350, 201214182012
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept